This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

COMPETE Phase III Clinical Trial 

to evaluate the efficacy and safety of Targeted Radionuclide Therapy with n.c.a. 177Lu-Edotreotide in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

Patient Information

Patients and interested parties can find further information on the COMPETE trial subjects’ inclusion criteria as well as our listed participating clinical centers.

View Details

Healthcare Professionals

The trial is conducted worldwide in min. 12 countries at approx. 43 sites and is open for recruitment. Healthcare professionals who are interested in enrolling patients can find comprehensive background information on this site.